Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_1
5
71%
Ph phase_2
2
29%

Phase Distribution

5

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
2(28.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Completed4
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (71.4%)
Phase 22 (28.6%)

Trials by Status

unknown114%
completed457%
terminated229%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_2

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

NCT00862134
terminatedphase_2

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

NCT00544674
completedphase_1

PR-104 in Treating Patients With Advanced Solid Tumors

NCT00349167
unknownphase_1

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

NCT01037556
completedphase_1

PR104 and G-CSF in Treating Patients With Solid Tumors

NCT00616213
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00862134Phase 2

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Terminated
NCT00544674Phase 2

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Terminated
NCT00349167Phase 1

PR-104 in Treating Patients With Advanced Solid Tumors

Completed
NCT01037556Phase 1

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

Unknown
NCT00616213Phase 1

PR104 and G-CSF in Treating Patients With Solid Tumors

Completed
NCT01358227Phase 1

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

Completed
NCT00459836Phase 1

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7